We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 07, 2020

Buparlisib Plus Tamoxifen in Pretreated HR+, HER2− Advanced Breast Cancer Stratified for PIK3CA Mutations

Cancer Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Medicine
Buparlisib in Combination With Tamoxifen in Pretreated Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Molecularly Stratified for PIK3CA Mutations and Loss of PTEN Expression
Cancer Med 2020 Apr 30;[EPub Ahead of Print], A Welt, M Wiesweg, S Theurer, W Abenhardt, M Groschek, L Müller, J Schröder, M Tewes, M Chiabudini, K Potthoff, A Bankfalvi, N Marschner, M Schuler, F Breitenbücher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading